This is an open-label, study of MEDI9090 to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of MEDI9090 in adult subjects with advanced solid tumors.

Inclusion Criteria:

• Male and female subjects
• 18 years and older
• Must have histologic documentation of advanced solid tumors
• Must have received and have progressed, are refractory or, intolerant to standard therapy and must not have a curative therapy option

Exclusion Criteria:

• Concurrent enrollment in another clinical study
• Prior participation in clinical studies that include durvalumab alone or in combination
• Concurrent chemotherapy, immunotherapy, biologic, or hormonal therapy for cancer treatment